AFP and liver cancer: Recently, a number of disease-biomarker aptamers were successfully selected by microfluidic technology, such as platelet derived growth factor BB (PDGF-BB) protein for various pathological states, myoglobin for cardiovascular disease, and alpha-fetoprotein for liver cancers (Huang et al., 2010, 2012; Weng et al., 2013).